Platelet perturbations in diabetes: Implications for cardiovascular disease risk and treatment

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 5, 2009, Pages 541-549

  Mathewkutty, Shiny ^a   McGuire, Darren K ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Antiplatelet therapy; Cardiovascular disease; Diabetes mellitus

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; INSULIN; NITROUS OXIDE; OMEGA 3 FATTY ACID; PLACEBO; PRASUGREL; PROSTACYCLIN; SIMVASTATIN; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; TIROFIBAN; PYRIDINE DERIVATIVE;

ANTICOAGULANT THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSAL ATTRIBUTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; IN-STENT RESTENOSIS; INSULIN RESISTANCE; LOADING DRUG DOSE; LOW DRUG DOSE; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRIMARY PREVENTION; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; THROMBOCYTE DISORDER; BLOOD; DRUG ANTAGONISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY; RISK; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

ASPIRIN; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PYRIDINES; RISK;

EID: 68949212906     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.30     Document Type: Review

References (85)

1. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care 21(7), 1138-1145 (1998).
2. McGuire DK, Emanuelsson H, Granger CB et al.; GUSTO IIb Investigators. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. Eur. Heart J. 21(21), 1750-1758 (2000).
3. McGuire DK, Newby LK, Bhapkar MV et al. Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. Am. Heart J. 147(2), 246-252 (2004).
4. Brunner EJ, Shipley MJ, Witte DR, Fuller JH, Marmot MG. Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study. Diabetes Care 29(1), 26-31 (2006).
5. Muhlestein JB, Anderson JL, Horne BD et al. Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. Am. Heart J. 146(2), 351-358 (2003).
6. Fox CS, Coady S, Sorlie PD et al. Trends in cardiovascular complications of diabetes. JAMA 292(20), 2495-2499 (2004).
7. Kearney PM, Blackwell L, Collins R et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371(9607), 117-125 (2008).
8. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110(2), 227-239 (2004).
9. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care 31 (Suppl. 1), S12-S54 (2008).
10. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289(19), 2560-2572 (2003).
11. Fruchart JC, Sacks FM, Hermans MP et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab. Vasc. Dis. Res. 5(4), 319-335 (2008).
12. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med. 358(24), 2545-2559 (2008).
13. Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with Type 2 diabetes. N. Engl. J. Med. 358(24), 2560-2572 (2008).
14. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with Type 2 diabetes. N. Engl. J. Med. 360(2), 129-139 (2009).
15. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in Type 2 diabetes. N. Engl. J. Med. 359(15), 1577-1589(2008).
16. Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366(9500), 1849-1861 (2005).
17. Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357(21), 2109-2122 (2007).
18. Natarajan A, Zaman AG, Marshall SM. Platelet hyperactivity in Type 2 diabetes: role of antiplatelet agents. Diab. Vasc. Dis. Res. 5(2), 138-144 (2008).
19. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in Type 2 diabetes. Diabetes Care 24(8), 1476-1485 (2001).
20. Tschoepe D, Roesen P, Schwippert B, Gries FA. Platelets in diabetes: the role in the hemostatic regulation in atherosclerosis. Semin. Thromb. Hemost. 19(2), 122-128 (1993).
21. Winocour PD. Platelet abnormalities in diabetes mellitus. Diabetes 41 (Suppl. 2), 26-31 (1992).
22. Erlinge D, Varenhorst C, Braun OO et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J. Am. Coll Cardiol. 52(24), 1968-1977 (2008).
23. Evangelista V, de Berardis G, Totani L et al. Persistent platelet activation in patients with Type 2 diabetes treated with low doses of aspirin. J. Thromb. Haemost. 5(11), 2197-2203 (2007).
24. Serebruany VL, Malinin AI, Pokov A, Bareness G, Hanley DF. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the Plavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial. Am. Heart J. 155(1), 93.e1-93.e7 (2008).
25. Serebruany VL, Malinin AI, Pokov AN, Hanley DF. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with Type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial. Clin. Ther. 30(2), 249-259 (2008).
26. Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J. Thromb. Haemost. 1(7), 1575-1579 (2003).
27. Juhan-Vague I, Alessi MC, Joly P et al. Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response. Arteriosclerosis 9(3), 362-367 (1989).
28. Inui Y, Suehiro T, Kumon Y, Hashimoto K. Platelet volume and urinary prostanoid metabolites in non-insulin-dependent diabetes mellitus. J. Atheroscler Thromb. 1(2), 108-112 (1994).
29. Yilmaz MB, Cihan G, Guray Y et al. Role of mean platelet volume in triagging acute coronary syndromes. J. Thromb. Thrombolysis, 26(1), 49-54 (2008).
30. Halushka PV, Rogers RC, Loadholt CB, Colwell JA. Increased platelet thromboxane synthesis in diabetes mellitus. J. Lab. Clin. Med. 97(1), 87-96 (1981).
31. Kwaan HC, Colwell JA, Cruz S, Suwanwela N, Dobbie JG. Increased platelet aggregation in diabetes mellitus. J. Lab. Clin. Med. 80(2), 236-246 (1972).
32. Trovati M, Anfossi G, Massucco P et al. Insulin stimulates nitric oxide synthesis in human platelets and, through nitric oxide, increases platelet concentrations of both guanosine-3′, 5′-cyclic monophosphate and aderiosine-3′, 5′-cyclic monophosphate. Diabetes 46(5), 742-749 (1997).
33. Phillips DR, Law D, Scarborough RM. Glycoprotein IIb-IIIa in platelet aggregation: an emerging target for the prevention of acute coronary thrombotic occlusions. Arch. Pathol. Lab. Med. 122(9), 811-812 (1998).
34. Tschoepe D, Roesen P, Kaufmann L et al. Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur.J. Clin. Invest. 20(2), 166-170 (1990).
35. Omoto S, Nomura S, Shouzu A et al. Significance of platelet-derived microparticles and activated platelets in diabetic nephropathy. Nephron 81(3), 271-277 (1999).
36. Diamant M, Nieuwland R, Pablo RF et al. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated Type 2 diabetes mellitus. Circulation 106(19), 2442-2447 (2002).
37. Jennings LK, Haga JH, Slack SM. Differential expression of a ligand induced binding site (LIBS) by GP IIb-IIIa ligand recognition peptides and parenteral antagonists. Thromb. Haemost. 84(6), 1095-1102 (2000).
38. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 26(7), 2181-2188 (2003).
39. Winocour PD. Platelet turnover in advanced diabetes. Eur. J. Clin. Invest. 24(Suppl. 1), 34-37 (1994).
40. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur. Heart J. 27(6), 647-654 (2006).
41. Mega JL, Close SL, Wiviott SD et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360(4), 354-362 (2009).
42. Pontiggia L, Lassila R, Pederiva S et al. Increased platelet-collagen interaction associated with double homozygosity for receptor polymorphisms of platelet GPIa and GPIIIa. Arterioscler. Thromb. Vasc. Biol. 22(12), 2093-2098 (2002).
43. Michos ED, Ardehali R, Blumenthal RS, Lange RA, Ardehali H. Aspirin and clopidogrel resistance. Mayo Clin. Proc. 81(4), 518-526 (2006).
44. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler. Thromb. Vasc. Biol. 26(8), 1895-1900 (2006).
45. McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb. Haemost. 88(5), 711-715 (2002).
46. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329), 71-86 (2002).
47. Smith SC Jr, Allen J, Blair SN et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113(19), 2363-2372 (2006).
48. Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus. Diabetologia 51(3), 385-390 (2008).
49. Gresner P, Dolnik M, Waczulikova I et al. Increased blood plasma hydrolysis of acetylsalicylic acid in Type 2 diabetic patients: a role of plasma esterases. Biochim. Biophys. Acta 1760(2), 207-215 (2006).
50. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 268(10), 1292-1300 (1992).
51. Colwell JA. Aspirin therapy in diabetes. Diabetes Care 27(Suppl. 1), S72-S73 (2004).
52. Buse JB, Ginsberg HN, Bakris GL et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 115(1), 114-126 (2007).
53. Ryden L, Standl E, Bartnik M et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur. Heart J. 28(1), 88-136 (2007).
54. Hansson L, Zanchetti A, Carruthers SG et al.; the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351(9118), 1755-1762 (1998).
55. Harpaz D, Gottlieb S, Graff E et al.; Israeli Bezafibrate Infarction Prevention Study Group. Effects of aspirin treatment on survival in non-insulin-dependent diabetic patients with coronary artery disease. Am. J. Med. 105(6), 494-499 (1998).
56. Cubbon RM, Gale CP, Rajwani A et al. Aspirin and mortality in patients with diabetes sustaining acute coronary syndrome. Diabetes Care 31(2), 363-365 (2008).
57. Sacco M, Pellegrini F, Roncaglioni MC et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in Type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 26(12), 3264-3272 (2003).
58. Belch J, MacCuish A, Campbell I et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337, a1840 (2008).
59. Ogawa H, Nakayama M, Morimoto T et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with Type 2 diabetes: a randomized controlled trial. JAMA 300(18), 2134-2141 (2008).
60. De Berardis G, Sacco M, Evangelista V et al.; ACCEPT-D Study Group. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 8, 21 (2007).
61. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N. Engl.J. Med. 338(21), 1498-1505 (1998).
62. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Angina Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N. Engl. J. Med. 338(21), 1488-1497 (1998).
63. The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N. Engl. J. Med. 339(7), 436-443 (1998).
64. O'Shea JC, Hafley GE, Greenberg S et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stem intervention: the ESPRIT trial: a randomized controlled trial. JAMA 285(19), 2468-2473 (2001).
65. The CAPTURE Investigators: Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 349, 1429-1435 (1997).
66. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 357(9272), 1915-1924 (2001).
67. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N. Engl. J. Med. 330(14), 956-961 (1994).
68. Topol EJ, Moliterno DJ, Herrmann HC et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N. Engl. J. Med. 344(25), 1888-1894 (2001).
69. Roffi M, Chew DP, Mukherjee D et al. Platelet glycoprotein IIb/ IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 104(23), 2767-2771 (2001).
70. Anderson JL, Adams CD, Antman EM et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons; endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 116(7), e148-e304 (2007).
71. Bhatt DL, Marso SP, Lincoff AM et al. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J. Am. Coll Cardiol. 35(4), 922-928 (2000).
72. Labinaz M, Madan M, O'Shea JO et al. Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/ IIIa Receptor With Integrilin Therapy [ESPRIT] Trial). Am. J. Cardiol. 90(6), 585-590 (2002).
73. Mehilli J, Kastrati A, Schuhlen H et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 110(24), 3627-3635 (2004).
74. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348(9038), 1329-1339 (1996).
75. Bhatt DL, Marso SP, Hirsch AT et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am. J. Cardiol. 90(6), 625-628 (2002).
76. Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345 (7), 494-502 (2001).
77. Beinart SC, Kolm P, Veledar E et al. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J. Am. Coll. Cardiol. 46(5), 761-769 (2005).
78. Chen ZM, Jiang LX, Chen YP et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366(9497), 1607-1621 (2005).
79. Angiolillo DJ, Shoemaker SB, Desai B et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115(6), 708-716 (2007).
80. Alfonso F, Angiolillo DJ. Platelet function assessment to predict outcomes after coronary interventions: hype or hope? J. Am. Coll. Cardiol. 48(9), 1751-1754 (2006).
81. Angiolillo DJ. Tackling the diabetic platelet: is high clopidogrel dosing the answer? J. Thromb. Haemost. 4(12), 2563-2565 (2006).
82. 12 inhibitory effects induced by clopidogrel on platelet procoagulant activity in Type 2 diabetes mellitus patients. Thromb. Res. DOI: 10.1016/j.thromres.2008.10.001 (2008).
83. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Platelet function profiles in patients with Type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54(8), 2430-2435 (2005).
84. Jakubowski JA, Winters KJ, Naganuma H, Wallentin L. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies. and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc. Drug Rev. 25(4), 357-374 (2007).
85. Wiviott SD, Braunwald E, Angiolillo DJ et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation 118(16), 1626-1636 (2008).